实用肿瘤学杂志 ›› 2013, Vol. 27 ›› Issue (4): 295-302.doi: 10.3969/j.issn.1002-3070.2013.04.002

• 论著 • 上一篇    下一篇

喉鳞癌中KAI1/CD82、MRP1/CD9的表达及意义

张炳辉1, 冯佳朋1, 邢文缘1, 徐秀玉2, 李晓丹1, 王宇1   

  1. 1.哈尔滨医科大学附属第二医院耳鼻咽喉头颈外科(哈尔滨 150086);
    2.哈尔滨医科大学附属肿瘤医院头颈外科
  • 收稿日期:2013-03-20 出版日期:2013-08-28 发布日期:2013-08-13
  • 通讯作者: 徐秀玉, E-mail:19661994@sina.com
  • 作者简介:张炳辉, 男, (1966-), 博士, 副主任医师, 从事头颈部肿瘤的基础及临床研究
  • 基金资助:
    黑龙江省教育厅科技基金面上项目(11531101)

The expression and significance of KAI1/CD82 and MRP1/CD9 in laryngeal squamous cell carcinomas

ZHANG Binghui1, FENG Jiapeng1, XING Wenyuan1, XU Xiuyu2, LI Xiaodan1, WANG Yu1   

  1. 1.Department of Otolaryngology/Head and Neck Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China;
    2.Department of Head and Neck Surgery, The Affiliated Tumor Hospital of Harbin Medical University
  • Received:2013-03-20 Online:2013-08-28 Published:2013-08-13

PDF

58

摘要： 目的探讨喉鳞癌中KAI1/CD82和MRP1/CD9的表达及意义。方法 采用实时荧光定量PCR法(RT-qPCR)及免疫组织化学技术检测100例喉鳞癌(Laryngeal squamous cell carcinoma, LSCC)组织及随机抽取30例相应癌旁非癌组组织中KAI1/CD82和MRP1/CD9的表达情况, 并分析二者与肿瘤临床病理参数的关系及对生存函数的影响。结果 在mRNA及蛋白水平上KAI1/CD82和MRP1/CD9表达结果基本是一致的, KAI1/CD82和MRP1/CD9在30例配对的LSCC中, 癌组织表达显著低于相应癌旁非癌组织, 其表达差异有统计学意义(P＜0.05);两者在TNM分期Ⅲ~Ⅳ、分化程度差、临床分期Ⅲ~Ⅳ、有淋巴结转移LSCC中的表达水平均低于在TNM分期Ⅰ~Ⅱ、分化程度良、临床分期Ⅰ~Ⅱ、无淋巴结转移LSCC患者(P＜0.05)。而在不同性别、不同年龄组、不同生长部位等LSCC患者的组织中其表达差异无统计学意义(P＞0.05);LSCC中KAI1/CD82蛋白阳性表达者中位生存期为78个月, 高于阴性表达者的48个月(χ2=6.98, P=0.008), LSCC中MRP1/CD9蛋白阳性表达者中位生存期为78个月, 高于阴性表达者的49个月(χ2=5.45, P=0.02);在LSCC中KAI1/CD82和MRP1/CD9蛋白的表达呈正相关(χ2=31.41, P＜0.01)。结论 KAI1/CD82和MRP1/CD9可能共同参与了LSCC的发生发展过程, 对LSCC的浸润和转移及预后评估具有一定的临床参考价值。KAI1/CD82、MRP1/CD9可以作为判断喉鳞癌浸润转移及预后的标记物。

Abstract: Objective The expressions and significance of KAI1/CD82 and MRP1/CD9 in laryngeal squamous cell carcinoma(LSCC)were investigated.Methods Real-time quantitative PCR(Q-PCR)and immunohistochemical technique were employed to detect the expressions of KAI1/CD82 and MRP1/CD9 in the laryngeal tissues of 100 LSCC patients, randomly selected 30 cases of corresponding adjacent non-cancerous tissues as well as the influence of both proteins on the clinicopathological features and survival of LSCC patients.Results The changes in mRNA and protein expressions of KAI1/CD82 and MRP1/CD9 were consistent in two groups, and the expressions of KAI1/CD82 and MRP1/CD9 were significantly different among two groups(P＜0.01 or ＜0.05).The KAI1/CD82 and MRP1/CD9 expressions in patients with TNM stage Ⅲ~Ⅳ LSCC, poorly differentiated LSCC, clinical stage Ⅲ~Ⅳ LSCC or lymph node metastasis was markedly lower than that in those with TNM stage Ⅰ~Ⅱ LSCC, well differentiated LSCC, clinical stage Ⅰ~Ⅱ LSCC or no lymph node metastasis(P＜0.01 or ＜0.05).However, there was no marked difference in KAI1/CD82 and MRP1/CD9 expressions between males and females among patients in different age LSCC different parts and tissues(P＞0.05).In LSCC patients positive for KAI1/CD82 protein expression, the median survival time was 78 months, which was significantly longer than that in LSCC patients negative for KAI1/CD82 protein expression(48 months;χ2=6.98, P=0.008).In LSCC patients positive for MRP1/CD9 protein expression, the median survival time was 78 months, which was significantly longer than that in LSCC patients negative for KAI1/CD82 protein expression(49 months;χ2=5.45, P=0.02).Expression was positively correlated with KAI1/CD82 in LSCC and MRP1/CD9 protein(χ2=31.41, P＜0.01).Conclusion Both KAI1/CD82 and MRP1/CD9 are involved in the occurrence and development of LSCC, and may provide clinical information for evaluation of invasiveness, metastasis and prognosis of LSCC.Thus, KAI1/CD82 and MRP1/CD9 may serve as markers for determination of invasiveness, metastasis and prognosis of LSCC.

中图分类号: 

京ICP备05021913-4号
版权所有 © 2019 《实用肿瘤学杂志》编辑部
地址：哈尔滨市南岗区保健路6号　邮编：150081 　电话：0451-86298293　86623347　 传真：0451-86665003　E-mail： syzlxzz@126.com
本系统由北京玛格泰克科技发展有限公司设计开发